BACKGROUND: Although Mycoplasma genitalium (MG) is an acknowledged cause of nongonococcal urethritis (NGU), access to diagnostic testing is limited. Syndromic management is common, yet little is known about natural history. METHODS: Between August 2014 and April 2016, 13 heterosexual men aged ≥16 years with MG were identified within a cohort study of men with and without NGU attending an urban sexually transmitted diseases clinic. Men had 6-7 monthly visits. NGU was defined as ≥5 polymorphonuclear leukocytes per high-power field on urethral Gram stain plus either visible urethral discharge or urethral symptoms. Men with NGU received 1 g of azithromycin. Men with persistent NGU received moxifloxacin 400 mg for 14 days. First-void urine was retrospectively tested for MG using transcription-mediated amplification. Resistance-associated mutations were detected by polymerase chain reaction (PCR) and sequencing. Organism load was determined by quantitative PCR. RESULTS: Sixty-two percent of MG-positive men had macrolide resistance-mediating mutations (MRMM) at enrollment; 31% had parC mutations (all outside the quinolone resistance-determining region). MG persisted after azithromycin in 7 men, 6 of whom had MRMM. The median duration of persistence in the absence of curative therapy was 143 days (range, 21-228). Five men experienced symptom resolution after azithromycin, but MG persisted for another 89-186 days before moxifloxacin. Organism load was somewhat lower in MRMM than wild-type infections (P = .16). CONCLUSIONS: The high prevalence of macrolide resistance and long duration of infection after symptom resolution highlights the need for diagnostic MG testing of men with NGU to direct therapy.
BACKGROUND: Although Mycoplasma genitalium (MG) is an acknowledged cause of nongonococcal urethritis (NGU), access to diagnostic testing is limited. Syndromic management is common, yet little is known about natural history. METHODS: Between August 2014 and April 2016, 13 heterosexual men aged ≥16 years with MG were identified within a cohort study of men with and without NGU attending an urban sexually transmitted diseases clinic. Men had 6-7 monthly visits. NGU was defined as ≥5 polymorphonuclear leukocytes per high-power field on urethral Gram stain plus either visible urethral discharge or urethral symptoms. Men with NGU received 1 g of azithromycin. Men with persistent NGU received moxifloxacin 400 mg for 14 days. First-void urine was retrospectively tested for MG using transcription-mediated amplification. Resistance-associated mutations were detected by polymerase chain reaction (PCR) and sequencing. Organism load was determined by quantitative PCR. RESULTS: Sixty-two percent of MG-positive men had macrolide resistance-mediating mutations (MRMM) at enrollment; 31% had parC mutations (all outside the quinolone resistance-determining region). MG persisted after azithromycin in 7 men, 6 of whom had MRMM. The median duration of persistence in the absence of curative therapy was 143 days (range, 21-228). Five men experienced symptom resolution after azithromycin, but MG persisted for another 89-186 days before moxifloxacin. Organism load was somewhat lower in MRMM than wild-type infections (P = .16). CONCLUSIONS: The high prevalence of macrolide resistance and long duration of infection after symptom resolution highlights the need for diagnostic MG testing of men with NGU to direct therapy.
Authors: T Deguchi; S Maeda; M Tamaki; T Yoshida; H Ishiko; M Ito; S Yokoi; Y Takahashi; S Ishihara Journal: J Antimicrob Chemother Date: 2001-11 Impact factor: 5.790
Authors: Kaitlin A Tagg; Neisha J Jeoffreys; Deborah L Couldwell; Jennifer A Donald; Gwendolyn L Gilbert Journal: J Clin Microbiol Date: 2013-05-08 Impact factor: 5.948
Authors: Jennifer K H Wroblewski; Lisa E Manhart; Kathleen A Dickey; Marie K Hudspeth; Patricia A Totten Journal: J Clin Microbiol Date: 2006-09 Impact factor: 5.948
Authors: Judith Vandepitte; Helen A Weiss; Nassim Kyakuwa; Susan Nakubulwa; Etienne Muller; Anne Buvé; Patrick Van der Stuyft; Richard Hayes; Heiner Grosskurth Journal: Sex Transm Dis Date: 2013-05 Impact factor: 2.830
Authors: Dionne C Gesink; Gert Mulvad; Ruth Montgomery-Andersen; Upaluk Poppel; Stephan Montgomery-Andersen; Aka Binzer; Lee Vernich; Gillian Frosst; Flemming Stenz; Elizabeth Rink; Ove Rosing Olsen; Anders Koch; Jørgen Skov Jensen Journal: Int J Circumpolar Health Date: 2012-04-16 Impact factor: 1.228
Authors: Evelyn Toh; Xiang Gao; James A Williams; Teresa A Batteiger; Lisa A Coss; Michelle LaPradd; Jie Ren; William M Geisler; Yue Xing; Qunfeng Dong; David E Nelson; Stephen J Jordan Journal: Sex Transm Dis Date: 2022-01-01 Impact factor: 2.830
Authors: Teck-Phui Chua; Kaveesha Bodiyabadu; Dorothy A Machalek; Suzanne M Garland; Catriona S Bradshaw; Erica L Plummer; Jennifer Danielewski; Lenka A Vodstrcil; Michelle L Doyle; Gerald L Murray Journal: J Med Microbiol Date: 2021-09 Impact factor: 2.472
Authors: Lisa E Manhart; Patricia A Totten; Gwendolyn E Wood; Nicole L Jensen; Sabina Astete; Jørgen S Jensen; George E Kenny; Christine M Khosropour; Catherine W Gillespie Journal: J Clin Microbiol Date: 2021-08-18 Impact factor: 5.948
Authors: Emily Rowlinson; James P Hughes; Laura C Chambers; M Sylvan Lowens; Jennifer L Morgan; Tashina S Robinson; Sarah S Romano; Gina L Leipertz; Olusegun O Soge; Matthew R Golden; Lisa E Manhart Journal: Sex Transm Dis Date: 2021-05-01 Impact factor: 2.830
Authors: Barbara Van Der Pol; Ken B Waites; Li Xiao; Stephanie N Taylor; Arundhati Rao; Melinda Nye; Steven Chavoustie; Aaron Ermel; Clair Kaplan; David Eisenberg; Philip A Chan; Leandro Mena; Sixto Pacheco; Smitha Krishnamurthy; Ruchika Mohan; Rasa Bertuzis; Chris L McGowin; Rodney Arcenas; Elizabeth M Marlowe Journal: J Clin Microbiol Date: 2020-05-26 Impact factor: 5.948
Authors: Gwendolyn E Wood; Stefanie L Iverson-Cabral; Catherine W Gillespie; M Sylvan Lowens; Lisa E Manhart; Patricia A Totten Journal: PLoS One Date: 2020-10-12 Impact factor: 3.240
Authors: Anne Hammer; Patti E Gravitt; Rachael Adcock; Nicole Patterson; Jack Cuzick; Cosette M Wheeler Journal: Sex Transm Dis Date: 2021-12-01 Impact factor: 2.830